Filtered By:
Therapy: Hormonal Therapy

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 218 results found since Jan 2013.

Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study
Conclusions: Vaginal estrogen use was not associated with a higher risk of cardiovascular disease or cancer. Our findings lend support to the safety of vaginal estrogen use, a highly effective treatment for genitourinary syndrome of menopause.
Source: Menopause - June 1, 2019 Category: OBGYN Tags: Original Articles Source Type: research

Cardiovascular Risk/Benefit Profile of MHT.
Conclusion: CV risk calculation should be considered by clinicians in order to exclude patients with high CV risk, in whom MHT is contraindicated. Assessing risks and benefits in a patient-centered approach according to individual's features, health status, and personal preferences is important in order to realize a safe and effective treatment. PMID: 31500138 [PubMed - in process]
Source: Medicina (Kaunas) - September 5, 2019 Category: Universities & Medical Training Authors: Villa P, Amar ID, Shachor M, Cipolla C, Ingravalle F, Scambia G Tags: Medicina (Kaunas) Source Type: research

HRT reduces morbidity and mortality in women with Turner sydrome
Women undergoing hormone therapy for Turner syndrome found to have reduced risk of diabetes, osteoporotic fractures and stroke, according to findings published inThe Journal of Clinical Endocrinology& Metabolism. Healio
Source: Society for Endocrinology - October 4, 2019 Category: Endocrinology Source Type: news

41-year-old has stroke a month after being treated at hormone clinic
A CBS News investigation reveals a growing trend at health clinics nationwide that could be putting patients at risk. Clinics are selling hormone therapy treatment some believe provides a fountain of youth. But as Dr. Jonathan LaPook shows us, people are finding out about the dangers of some clinics' practices the hard way.
Source: Health News: CBSNews.com - October 16, 2019 Category: Consumer Health News Source Type: news

Gen X Women Get Less Sleep Than Any Other Generation. What ’s Keeping Them Up?
In the middle of the night, I wake up feeling warm. I open the window and pull my hair back into a ponytail and drink some water. Then I glance at my phone, delete a few things, and see some spam. I hit unsubscribe and go back to bed. Then I lie there thinking, What if by opening that spam email I got myself hacked? What if I just sent everyone in my contact list a Burger King ad at two in the morning? Now wide awake, I move on to other concerns: my parents’ health, my stepson’s college tuition, pending deadlines. Hours roll by. I tackle real-life math problems: how many weeks I have before getting my next free...
Source: TIME: Health - January 6, 2020 Category: Consumer Health News Authors: Ada Calhoun Tags: Uncategorized Gen X healthy sleep insomnia Source Type: news

The critical period for neuroprotection by estrogen replacement therapy and the potential underlying mechanisms.
Abstract 17β-Estradiol (estradiol or E2) is a steroid hormone that has been broadly applied as a neuroprotective therapeutic for a variety of neurodegenerative and cerebrovascular disorders such as ischemic stroke, Alzheimer's disease, and Parkinson's disease. Several laboratory and clinical studies have reported that estrogen replacement therapy (ERT) had no effect against these diseases in elderly postmenopausal women, and at worst, increased their risk of onset and mortality. This review focuses on the growing body of data from in vitro and animal models characterizing the potential underlying mechanisms and s...
Source: Current Neuropharmacology - January 22, 2020 Category: Drugs & Pharmacology Authors: Guo H, Liu M, Zhang L, Wang L, Hou W, Ma Y, Ma Y Tags: Curr Neuropharmacol Source Type: research

The Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groups
Conclusion: The decline in ET utilization had differential disease and expenditure consequences by age groups in the United States. These results are limited by the lack of inclusion of vasomotor symptom benefit and costs of alternative medications for these symptoms in the analysis.
Source: Menopause - May 29, 2020 Category: OBGYN Tags: Original Studies Source Type: research

Prostate Cancer Drug Could Be ' Game Changing, ' Researchers Say
FRIDAY, May 29, 2020 -- For men with advanced prostate cancer, a new hormone therapy pill works better than standard injections -- and carries a much lower risk of heart attack or stroke, a clinical trial has found. The drug, called relugolix, is...
Source: Drugs.com - Daily MedNews - May 29, 2020 Category: General Medicine Source Type: news

Prostate Cancer Drug Could Be 'Game Changing'
For men with advanced prostate cancer, a new hormone therapy pill works better than standard injections -- and carries a much lower risk of heart attack or stroke.
Source: WebMD Health - May 29, 2020 Category: Consumer Health News Source Type: news

Loss of Estrogen Efficacy Against Hippocampus Damage in Long-Term OVX Mice Is Related to the Reduction of Hippocampus Local Estrogen Production and Estrogen Receptor Degradation
AbstractPostmenopausal women experience a higher risk for neurodegenerative diseases, including cognitive impairment and ischemic stroke. Many preclinical studies have indicated that estrogen replacement therapy (ERT) may provide protective effects against these neurological diseases. However, the results of Women ’s Health Initiative (WHI) studies have led to the proposal of “critical period hypothesis,” which states that there is a precise window of opportunity for administering beneficial hormone therapy following menopause. However, the underlying molecular mechanisms require further characterizatio n. Here, we e...
Source: Molecular Neurobiology - June 14, 2020 Category: Neurology Source Type: research

Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
We present a narrative review of the benefits versus risks of using MHT in the management of postmenopausal osteoporosis. Current literature suggests robust anti-fracture efficacy of MHT in patients unselected for low BMD, regardless of concomitant use with progestogens, but with limited evidence of persisting skeletal benefits following cessation of therapy. Side effects include cardiovascular events, thromboembolic disease, stroke and breast cancer, but the benefit-risk profile differs according to the use of opposed versus unopposed oestrogens, type of oestrogen/progestogen, dose and route of delivery and, for cardiovas...
Source: Osteoporosis International - July 7, 2020 Category: Orthopaedics Source Type: research

A community-based study of demographics, medical and psychiatric conditions, and gender dysphoria/incongruence treatment in transgender/gender diverse individuals
ConclusionTransgender and gender diverse individuals represent a population who express various gender identities and are seeking gender-specific healthcare at increasing rates. Psychiatric illness is highly prevalent compared to the US population but there is no difference in the prevalence of CV risk factors including obesity, type 2 diabetes, hypertension, and dyslipidemia.
Source: Biology of Sex Differences - October 5, 2020 Category: Biology Source Type: research

Randomized Trial Evaluation of Benefits and Risks of Menopausal Hormone Therapy Among Women Aged 50-59.
Abstract The health benefits and risks of menopausal hormone therapy among women aged 50-59 years are examined in the Women's Health Initiative randomized, placebo-controlled trials using long-term follow-up data and a parsimonious statistical model that leverages data from older participants to increase precision. These trials enrolled 27,347 healthy post-menopausal women aged 50-79 at 40 U.S. clinical centers during 1993-1998, including 10,739 post-hysterectomy participants in a trial of conjugated equine estrogens, and 16,608 participants with uterus in the trial of these estrogens plus medroxyprogesterone acet...
Source: Am J Epidemiol - October 7, 2020 Category: Epidemiology Authors: Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, Wactawski-Wende J, Kuller LH, Wallace R, Johnson KC, Shadyab AH, Gass M, Manson JAE Tags: Am J Epidemiol Source Type: research

Cardiovascular Complications of Prostate Cancer Therapy
AbstractPurpose of reviewWith treatment advances, the most common cause of death in prostate cancer patients is cardiovascular disease. Discerning the contribution of prostate cancer treatment on cardiovascular complications versus the natural progression of cardiovascular disease remains an ongoing area of investigation. Evaluating the research and identifying opportunities for further investigation is critical for optimal care of this prostate cancer patient population.Recent findingsThe degree that hormone therapy contributes to cardiovascular morbidity and mortality remains uncertain with conflicting results from large...
Source: Current Treatment Options in Cardiovascular Medicine - November 12, 2020 Category: Cardiology Source Type: research

Transgender People Often Have Heart Risks: Study
THURSDAY, Nov. 12, 2020 -- Many transgender people who take hormone therapy have unaddressed risks for heart disease and stroke, a new study finds. These patients often have undiagnosed high blood pressure and high cholesterol, even in young...
Source: Drugs.com - Daily MedNews - November 12, 2020 Category: General Medicine Source Type: news